Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor

被引:6
|
作者
Nixon, Donald R. [1 ,2 ,3 ,4 ]
Flinn, Nicholas [1 ]
机构
[1] Trimed Eye Ctr, Barrie, ON L4M 4S5, Canada
[2] Royal Victoria Reg Hlth Ctr, Dept Surg, Barrie, ON, Canada
[3] Soldiers Mem Hosp, Dept Surg, Orillia, ON, Canada
[4] Northern Ontario Sch Med NOSM, Dept Surg, Sudbury, ON, Canada
来源
CLINICAL OPHTHALMOLOGY | 2021年 / 15卷
关键词
contrast sensitivity; residual deficit; functional impairment;
D O I
10.2147/OPTH.S304229
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: What is the level of visual function in patients with diabetic macular edema (DME) and retinal vein occlusion (RVO) post-stabilization with anti-vascular endothelial growth factor? Patients and Methods: This observational non-controlled single center study evaluated visual function in two patient populations with macular edema 25 with diabetic macular edema and 25 with retinal vein occlusion treated following standard protocol of anti-VEGF therapy post- stabilization. Results: A total of 68 eyes from 50 patients were analyzed including 18 bilateral and 7 unilateral diabetic macular edema, 14 patients with central and 11 with branch retinal vein occlusion. The mean age was 69 +/- 11 years and 64% were male. In the RVO group: LogMAR BCVA was 0.12 +/- 0.13 compared to the unaffected eye 0.04 +/- 0.05 (P=<0.01), contrast sensitivity in the treated eye was 1.69 +/- 0.21 log units compared to 1.84 +/- 0.15 log units in the unaffected eye (p=<0.01), the ganglion cell volume was 0.88 +/- 0.15 mm(3) in the treated eye compared to 1.04 +/- 0.1 mm(3) in the unaffected eye (P=<0.01). In the diabetic macular edema group: LogMAR BCVA was 0.17 +/- 0.13, contrast sensitivity in the treated eye was 1.16 +/- 0.21 log units compared to the normal population 1.92 +/- 0.8 log units (p=<0.01), the ganglion cell volume was 0.94 +/- 0.14 mm(3) in the treated eye compared to 1.03 +/- 0.12 mm(3) in the normal population (P=<0.001). In both groups a majority of treated eyes retained visual acuity >=+0.4 LogMAR (diabetic macular edema 95%, RVO 96%) however contrast sensitivity was more than two standard deviations below the normal population mean in a majority of treated eyes in both groups (diabetic macular edema 88% RVO 64%). Conclusion: Impairment in contrast sensitivity in both groups could impact activities of daily living including driving and should prompt questions about how we advise patients regarding their level of function and the potential limitations/restrictions that should be placed on such activities.
引用
收藏
页码:1659 / 1666
页数:8
相关论文
共 50 条
  • [31] Review of anti-vascular endothelial growth factor therapy in macular edema secondary to central retinal vein occlusions
    Mitra, Arijit
    Lip, Peck-Lin
    EXPERT REVIEW OF OPHTHALMOLOGY, 2011, 6 (06) : 623 - 629
  • [32] Fluctuations in Macular Thickness in Patients with Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents
    Chen, Andrew X.
    Greenlee, Tyler E.
    Conti, Thais F.
    Briskin, Isaac N.
    Singh, Rishi P.
    OPHTHALMOLOGY RETINA, 2020, 4 (12): : 1158 - 1169
  • [33] Characteristics of Patients Who Drop Out of Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Associated with Branch Retinal Vein Occlusion
    Kawakami, Setsuko
    Wakabayashi, Yoshihiro
    Watanabe, Yoko
    Umazume, Kazuhiko
    Yamamoto, Kaori
    Goto, Hiroshi
    JOURNAL OF OPHTHALMOLOGY, 2024, 2024
  • [34] Comparing Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion
    Sun, Jennifer K.
    JAMA OPHTHALMOLOGY, 2017, 135 (06) : 649 - 650
  • [35] ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION IN THE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ERA
    Tam, Emily K.
    Golchet, Pamela
    Yung, Madeline
    DeCroos, Francis C.
    Spirn, Marc
    Lehmann-Clarke, Lydia
    Ambresin, Aude
    Tsui, Irena
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (02): : 292 - 298
  • [36] Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema
    Koyanagi, Yoshito
    Yoshida, Shigeo
    Kobayashi, Yoshiyuki
    Kubo, Yuki
    Nakama, Takahito
    Ishikawa, Keijiro
    Nakao, Shintaro
    Hisatomi, Toshio
    Ikeda, Yasuhiro
    Oshima, Yuji
    Ishibashi, Tatsuro
    Sonoda, Koh-hei
    OPHTHALMOLOGICA, 2018, 239 (2-3) : 94 - 102
  • [37] Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion
    Marta S. Figueroa
    Inés Contreras
    Drugs, 2012, 72 : 2063 - 2071
  • [38] Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema
    Kelkar, Aditya
    Webers, Caroll
    Shetty, Rohit
    Kelkar, Jai
    Labhsetwar, Nikhil
    Pandit, Abhishek
    Malode, Madhulika
    Tidke, Sayali
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2020, 68 (10) : 2143 - 2147
  • [39] Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion
    Figueroa, Marta S.
    Contreras, Ines
    DRUGS, 2012, 72 (16) : 2063 - 2071
  • [40] Changes in Retinal Function and Structure Following Intravitreal Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Treatment for Diabetic Macular Edema
    de Sousa, Monique Viana
    Nepomuceno, Antonio Brunno
    Messias, Andre
    Jorge, Rodrigo
    Scott, Ingrid U.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)